Stephen Chan

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

D. Provencher, M. Gore, S. Chan, 2007, British Journal of Cancer.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.

S. Chan, F. Erdkamp, A. Płużańska, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Role of Blood Tumor Marker Measurement (Using a Biochemical Index Score and C-Erbb2) in Directing Chemotherapy in Metastatic Breast Cancer

S. Pinder, R. Blamey, S. Pinder, 2000, The International journal of biological markers.

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.

C. Sotiriou, C. Desmedt, D. Larsimont, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.